LiveChain Secures Senior Note from Humanyze, Aiming to Build New AI‑Enabled Business Unit

HIND
December 22, 2025

LiveChain, Inc. (OTC: LICH), a subsidiary of Vyome Holdings, entered into a binding letter of intent with Remus Capital on December 22, 2025 to acquire a senior secured convertible note issued by Humanyze, an AI‑enabled human‑resources analytics firm that originated from MIT’s Media Lab. The deal will make LiveChain the senior secured creditor of Humanyze, giving it a lien on all of the company’s intellectual property and trade secrets. In exchange, LiveChain will issue common stock valued at approximately $325,000 to Remus Capital, effectively transferring ownership of Humanyze’s brand and data assets to LiveChain.

Humanyze, founded in 2010 by MIT doctoral students, specializes in organizational network analysis that turns employee communication metadata into insights about workplace health and business process optimization. The company has built a portfolio of SOC 2 Type II and ISO 27001‑certified data platforms that never capture message content, focusing instead on privacy‑preserving analytics. While Humanyze’s financial performance is not publicly disclosed, the acquisition of its senior note gives LiveChain access to a technology that could generate new revenue streams in the high‑growth HR‑analytics market.

Remus Capital, a Boston‑based venture firm that invests in early‑stage technology companies, is divesting the note to realize value from its early investment in Humanyze. The firm’s decision to sell the note aligns with its strategy of rotating capital into newer opportunities while monetizing existing positions.

LiveChain has historically operated in live‑streaming and public‑chain technology, but its market capitalization remains very low and detailed financials are scarce. By acquiring Humanyze’s intellectual property and data assets, LiveChain positions itself to transform into a standalone, scalable business unit that can leverage Vyome Holdings’ broader AI strategy and U.S.–India innovation corridor.

Vyome Holdings, a clinical‑stage biotechnology company, reported a net loss of $9.2 million in Q3 2025 largely due to merger‑related charges, but the company has extended its cash runway through 2026. Chairman Krishna Gupta said the Humanyze acquisition “offers multiple monetization pathways and a compelling market opportunity.” CEO Venkat Nelabhotla added that the move is the first step toward making LiveChain self‑sufficient and building a scalable independent business.

The LOI is binding but subject to customary closing conditions, with definitive agreements expected within 30 days and closing within an additional 45 days. No market reaction data were available at the time of reporting.

revised_sentiment_rating

}

importance

medium

high

low

The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.